Evidence map›Paper›PMID 16940764›Full record

ReviewBehavioural pharmacology2006

Neuroprotective and disease-modifying effects of the ketogenic diet.

Maciej Gasior, Michael A Rogawski, Adam L Hartman

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Behavioural pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 203 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 6 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03328858 naterminatednot on this mapstarted 2017, after this paper: background citation

A Phase II Study of the Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor

TypeinterventionalSponsorNicklaus Children's Hospital f/k/a Miami Children's HospitalRan2017 to 2020Enrolled2ConditionsBrain TumorsArmsKetogenic Diet
NCT05469997 nacompletednot on this mapstarted 2023, after this paper: background citation

Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome

TypeinterventionalSponsorUniversity of British ColumbiaRan2023 to 2024Enrolled52ConditionsParkinson DiseaseArmsMediterranean-Ketogenic Diet, Mediterranean diet supplemented with medium-chain triglyceride oil
3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 6 syntheses or guidelines pooled it, 453 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Maciej GasiorEpilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-3702, USA. gasiorm@ninds.nih.gov
Michael A Rogawski
Adam L Hartman
Johns Hopkins University · USNational Institute of Neurological Disorders and Stroke · USNational Institutes of Health · US

Funding

PHARMACOLOGICAL STUDIES OF ION CHANNELS IN CULTURED CELLSZ01NS002732 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI THEODORE, WILLIAM · 1988 to 2008
$1.1M
PRECLINICAL EVALUATION OF NOVEL ANTICONVULSANT DRUGSZ01NS002877 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI ROGAWSKI, MICHAEL A. · 1993 to 2006
–
Intramural NIH HHS Z01 NS002877
6 · The paper itself

Abstract

The ketogenic diet has been in clinical use for over 80 years, primarily for the symptomatic treatment of epilepsy. A recent clinical study has raised the possibility that exposure to the ketogenic diet may confer long-lasting therapeutic benefits for patients with epilepsy. Moreover, there is evidence from uncontrolled clinical trials and studies in animal models that the ketogenic diet can provide symptomatic and disease-modifying activity in a broad range of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, and may also be protective in traumatic brain injury and stroke. These observations are supported by studies in animal models and isolated cells that show that ketone bodies, especially beta-hydroxybutyrate, confer neuroprotection against diverse types of cellular injury. This review summarizes the experimental, epidemiological and clinical evidence indicating that the ketogenic diet could have beneficial effects in a broad range of brain disorders characterized by the death of neurons. Although the mechanisms are not yet well defined, it is plausible that neuroprotection results from enhanced neuronal energy reserves, which improve the ability of neurons to resist metabolic challenges, and possibly through other actions including antioxidant and anti-inflammatory effects. As the underlying mechanisms become better understood, it will be possible to develop alternative strategies that produce similar or even improved therapeutic effects without the need for exposure to an unpalatable and unhealthy, high-fat diet.

Indexed as

Diet, Carbohydrate-RestrictedAlzheimer DiseaseAnimalsBrainCell SurvivalDietary FatsHumansKetone BodiesNeurodegenerative DiseasesNeuronsNeuroprotective AgentsParkinson DiseaseDietary FatsKetone BodiesNeuroprotective Agents

Identifiers

PMID16940764
PMCPMC2367001
OpenAlexW2112144930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.